JCOG

The Japan Clinical Oncology Group (JCOG) is the largest Japanese cooperative group funded primarily by the National Cancer Center Research and Development Fund.

BTSG:Brain Tumor Study Group / Publications

更新日:2013年11月8日

a. 論文

1. 委員会承認の治療研究

S Shibui, A Asai, T Fujimaki, et al.: Randomized Controlled Trial on Malignant Brain Tumors Activities of The Japan Clinical Oncology Group (JCOG)- Brain Tumor Study Group (BTSG) . Neurol med chirur. 44, 220-221, 2004.
S Shibui, Members of JCOG Brain Tumor Study Group: The result of a clinical trial for malignant gliomas by JCOG Brain Tumor Study Group. Neuro-Oncology. 11:892, 2009
S Shibui, Y Narita, J Mizusawa, et al.: Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer ChemotherPharmacol. 71, 511-521, 2013

2. グループ代表者管理の治療研究

なし  

3. 附随研究等

M Ohki, K Sakurada, Y Sonoda, et al.: Analysis of the extent of astrocytic tumour resection evaluated by magnetic resonance images. Neurosurg Rev. 26(4):262-265, 2003.
B Hu, P Guo, Q Fang, et al.: Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci. 100(15): 8904-8909, 2003.
Y Muragaki, K Suzukawa, H Iseki, et al.: Development of three-dimensional navigation system updated with intraoperative MRI. Computer Assisted Radiology and Surgery. 1360, 2003.
A Mukasa, K Ueki, A Asai, et al.: Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol. 14: 34-42, 2004.
M Fujimura, T Kumabe, H Tominaga, et al.: Routine clinical adoption of magnetic resonance imaging was associated with better outcome after surgery in elderly patients with a malignant astrocytic tumour : a retrospective review. Acta Neurochir(Wien). 146: 251-255, 2004.
T Kumabe, N Nakasato, K Nagamatsu, et al.: Intraoperative localization of the lip sensory area by somatosensory evoked potentials-technical note-. J Clin Neurosciece. 12(1): 66-70, 2004.
K Kamada, Y Sawamura, F Takeuchi, et al.: Gradual recovery from dyslexia and related serial magnetoencephalographic changes in the lexico-semantic centers after resection of a mesial temporal astrocytoma. J Neurosurg. 100: 1101-1106, 2004.
Y Yoshida, K Tanaka, T Hashimoto: The significance of lipid resonances in proton MR spectroscopy of brain tumors. 聖マリアンナ医科大学雑誌. 32(4): 329-338, 2004.
A Mukasa, K Ueki, R Nishikawa, et al.: Selective Expression of a Subset of Neuronal Genes in Oligodendroglioma with chromosome 1p loss. Brain Pathology. 14: 34-42, 2004.
R Nishikawa, T Sugiyama, Y Narita, et al.: Immunohistochemical analysis of the mutant epidermal growth factor ΔEGFR, in glioblastoma. Brain Tumor Pathology. 21: 53-56, 2004.
N Hata, Y Muragaki, T Inomata, et al.: Intraoperative tumor segmentation and volume measurement in MRI-guided glioma surgery for tumor resection rate control. Acad Radiol. 12: 116-122, 2004.
Y Muragaki, H Iseki, T Maruyama, et al.: Advanced information-guided surgery by integration of data from different modality. Computer Assisted Radiology and Surgery 2004: International Congress Series. 1268: 693-696, 2004.
T Kumabe, N Nakasato, K Nagamatsu, et al.: Intraoperative localization of the lip sensory area by somatosensory evoked potentials-technical note-. J Clin Neurosci. 12 : 66-70, 2005.
S Yano, K Makino, H Nakamura, et al.: Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy. Neurol Med Chir. 45 : 294-298, 2005.
K Kamada, Y Sawamura, F Takeuchi, et al.: Functional identification of the primary motor area by corticospinal tractography. Neurosurg. 556 : 98-109, 2005.
M Tanaka, Y Ino, K Nakagawa, et al.: High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncology. 6 :953-960, 2005.
T Fujimaki : Surgical Treatment of brain metastasis. Int J Clini Oncol. 10 : 74-80, 2005.
K Yonemori, M Sumi: Progastrin- releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation. Cancer. 104 : 811-816, 2005.
Y Narita, S Shibui: Cases with carcinomatous meningitis and cerebral infarction. Jpn J Clin Oncol. 36:676, 2006.
K Sakurada, S Sato, Y Sonoda, et al: Surgical resection of the tumors located in subcortex of language area. Acta Neurochir (Wien). 149:123-130, 2006.
S Higano, X Yun, T Kumabe, et al.: Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 241: 839-846, 2006.
Y Muragaki, H Iseki, T Maruyama, et al.: Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir. Suppl 98: 67-75, 2006.
T Beppu, K Ogasawara, A Ogawa: Alleviation of intracranial air using carbon dioxide gas during intraventricular tumor resection. Clin Neurol Neurosurg. 108: 665-660, 2006.
T Serizawa, Y Higuchi, J Ono, et al.: Gammma knife radiosurgery for metastatic brain tumors without prophylactic whole-brain radiotherapy: result in 1000 consecutive cases. J Neurosurg. 105: 86-90, 2006.
H Aoyama, H Shirato, M Tago, et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 295:2483-2491, 2006.
T Kumabe, S Higano, S Takahashi, et al.: Ischemic complications associated with resection of opercular glioma. J Neurosurg. 106: 263-269, 2007.
K Sakurada, S Sato, Y Sonoda, et al.:Surgical resection of the tumors located in subcortex of language area. Acta Neurochir (Wien). 149:123-130, 2007.
渡辺茂樹,櫻田香, 毛利渉:補足運動野症候群を呈した神経膠腫手術例の検討. Brain Nerve. 59:793-796, 2007.
K Makino, H Nakamura, M Kudo, et al.: Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma. Neurol Med Chir. 47:229-232, 2007.
T Fujimaki, H Ishii, A Matsuno, et al.: Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide- refractory recurrent anaplastic astrocytoma. World J Surg Oncol. 5:89, 2007.
T Wakabayashi: A phase I clinical trial of interferon-beta gene therapy for high- grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med. 10:329-339, 2008.
T Wakabayashi: A multicenter phase I trial of interferon-β and temozolomide combination therapy for high-grade gliomas (INTEGRA study) Jpn J Clin Oncol. 38: 715-718, 2008.
Y Narita, S Shibui: Strategy of surgery and radiation therapy for brain metasta- ses. Int J Clin Oncol. 14:275-280, 2009.
S Shibui: Treatment of metastatic brain tumors. Int J Clin Oncol 214:273-274, 2009.
Y Sonoda, T Kumabe: Analysis of the IDH1 codon 132 mutations in Japanese glioma patients. Cancer Sci. 100:1996-1998, 2009.
Y Sonoda, T Kumabe: Long-term survivors of glioblastoma: Clinical features and molecular analysis. Acta Neurochir (Wien) 151:1349-1358, 2009.
T Hidaka, K Sugiyama: The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma. Anticancer Research. 29:597-603, 2009.
M Nagane: Prolonged and severe throm- bocytopenia with pancyto- penia induced by radiation- combined temozolomide therapy in a patient with newly-diagnosed gliobla- stoma-analysis of O6-methy- lguanine-DNA methyl- transferase status. J Neuro-Oncol. 92:227-232, 2009.
Y Sonoda , T Kumabe: O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. 15:352-358, 2010.
F Yamasaki, K Sugiyama: Glioblastoma treated with postoperative radio- chemotherapy: Prognostic value of apparent diffusion coefficient at MR imaging. European Journal of Radiology. 73:532-537, 2010.
K Motomura, T Wakabayashi: Benefits of Interferon-β and Temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer. 117:1721-1730, 2011.
J Adachi, R Nishikawa: O6-methylguanine -DNA methyltransferase promotormethylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and respoinse to temozolomide treatment. J Neuro Oncol. 107: 147-153, 2011.
K Motomura, T Wakabayashi: Benefits of Interferon-β and Temozolomide combina- tion therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer. 17: 1721-1730, 2011.
その他
H Aoyama, H Shirato, R Onimura, et al.: Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the Skull. Int Radiation Oncology Biol Phys. 56: 793-800, 2003.
H Endo, T Kumabe, H Jokura, et al.: Stereotactic radiosurgery for nodular dissemination of anaplastic ependymoma. Acta Neurochir (Wien). 146: 291-298, 2004.
Y Shibamoto, E Tsuchida, M Sumi, et al.: Primary central nervous system lymphoma in Japan 1995-1999: changes from the preceding 10 years. J Cancer Res Clin Oncol. 130(6): 351-356, 2004.
T Todo, Samuel D. Rabkin: Development of oncolytic replication-competent Herpes simplex virus vectors:The G207 paradigm. Humana Press. 199-210, 2004.
T Fujimaki: Cell biology of brain tumor: with special emphasis on tumor cell invasion. Neurosurgery Update 2004, Update in Spine surgery and Neuro-Oncology Jung H-W (ed). JMC. 157-160, 2004.
H Hirano, H Takeshima, M Niiro, et al.: The environment of increased concentration of docosa- hexaenoic acid in glioblastoma may suppress the anti-tumor effect of macrophages. Oncol Rep. 13 : 1185-1191, 2005.
H Takahashi : Stereotactic technique for radiofrequency antenna implantation for brain tumor treatment - Technical note and report of complications -. Jpn J Hyperthermic Oncol. 21: 221-229, 2005.
P Guo, Y Imanishi, FC Cackowski, et al.: Up-regulation of angiopoietin- 2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5γ2 correlates with the invasiveness of human glioma. Am J Path. 166: 877-890, 2005.
R Kanai, H Tomita, A Shinoda, et al.: Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of γ34.5-mediated virulence. Gene Ther. 13: 106-116, 2005.
Y Ino, Y Saeki, H Fukunaga, et al.: Triple combination of oncolytic Herpes Simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res. 12: 643-652, 2006.
K Kamada, F Takeuchi F, S Kuriki, et al.: Dissocitated expressive and receptive language functions on magnetoencephalography, functional magnetic resonance image, and amobarbital studies. J Neurosurg. 104: 598-607, 2006.
S Sugiyama, Y Yamashita, T Kikuchi, et al.: Safey and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor model. J Neurooncol. 82: 41-47, 2007.
K Kamada, Y Sawamura, F Takeuchi, et al.: Expressive and receptive language areas determined by a non-invasive reliable method co-using functional magnetic resonance imaging and magnetoencephalography. Neurosurgery. 60: 296-306, 2007.
N Nagane, WK Cavenee, Y Shiokawa: Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 106: 407-416, 2007.
T Aoki, R Nishikawa T, Mizutani, et al.: Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. Int J Oncol. 12: 341-349, 2007.
B Hu, P Guo, I Bar-Joseph, et al.: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene. 26: 5577-5586, 2007.
MJ Jarzynka, B Hu, KM Hui, et al.: ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. Cancer Res. 67: 7203-7211, 2007.
T Beppu, T Inoue, H Nishimoto, et al.: Preoperative imaging of superficially located glioma resection using short inversion-time inversion recovery images in high-field magnetic resonance imaging. Clin Neurol Neurosurg. 109: 327-334, 2007.
H Kashimura, T Inoue, T Beppu, et al.: Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy-Three case reports. Clin Neurol Neurosurg. 109: 106-110, 2007.
C Shinohara, Y Muragaki: Long-term prognostic assessment of 185 newly diagnosed gliomas- -gradeIII glioma showed prognosis comparable to that of grade II glioma. Jpn J Clin Oncol. 38: 730-733, 2008.
E Hirata, JA Takahashi: Endogenous tenascinc enhances glioblastoma invasion with reactive change of surrounding brain. Cancer Sci. 100: 1451-1459, 2009.
N Ozawa, Y Muragaki: Identification of thepyramidal tract by neuronavigation based on intraoperative diffusion-weighted imaging combined with subcortical stimulation. Stereotact Funct Neurosurg. 87: 18-24, 2009.
T Aoki, JA Takahashi: Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg. 112: 50-56, 2010.
M Nagane: Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro-Oncology. 12: 687-700, 2010.
T Beppu: Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas. J Neurooncol. 103: 619-627, 2010.
M Nagane: Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol. 12: 687-700, 2010.
K Yonemori, S Shibui: Disruption of the blood brain barrier by brain metastases of triple- negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer. 116: 302-308, 2010.
J Sunayama, C Kitanaka, et al.: FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells. 29: 1327-1337, 2011.
K Hashimoto, S Shibui, et al.: Comparison of clinical outcomes of surgery followed by local brain radiotherapy and surgery followed by whole brain radiotherapy in patients with single brain metastasis: single-center retrospective analysis. Int J Radiat Oncol. 15: e475-478, 2011.
M Ohno, S Shibui, et al.: Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide. Neurol Med Chir. 51: 728-731, 2011.
H Nakamura, J Kuratsu: Molecular and clinical analysis of glioblastoma with an oligodendroglial component(GBMO). Brain Tumor Pathology. 28: 185-190, 2011.
T Takezaki, J Kuratsu: Essential Role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Science. 102: 1306-1312, 2011.
R Saito, T Kumabe: Regression of recurrent glioblastoma infiltrate- ing the brainstem after convection- enhanced delivery of nimustine hydrochloride. J Neurosurg Pediatr. 7: 522-526, 2011.
F Yamasaki, K Sugiyama: Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neuro Oncol. 13: 791-801, 2011.
T Beppu: Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas. J Neuro Oncol. 103 :619-627, 2011.
T Ando, Y Muragaki: Precise comparison of protoporphyrin IX fluorescence spectra with pathological results for brain tumor tissue identification. Brain Tumor Pathol. 28: 43-51, 2011.
F Ohka, T Wakabayashi: The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PloS ONE. 6: E23332, 2011.
A Doskaliyev, K Sugiyama: Lymphomas and glioblas- tomas: differences in the apparent diffusion coefficient evaluated with high b-value diffu- sion-weighted magnetic resonance- imaging at 3T. Eur J Radiol. 81: 339-344, 2012.

4. 総説・解説

嘉山孝正:転移性脳腫瘍の治療戦略.吉田純.斎藤清編.脳神経外科の治療戦略と成績 - 前方視的調査2003-2004. 医学書院. 2005
佐藤慎哉、嘉山孝正:転移性脳腫瘍に対する臨床試験.脳神経外科速報. 15:937-942, 2005.
渋井壮一郎:悪性脳腫瘍治療の新しい展開 化学療法の新展開.Jpn J Cancer Chemother. 32 : 441-447, 2005.
渋井壮一郎、宮北康二、大西晶子、他: 星細胞腫grade3/4に対するACNU vs ACNU+PCZによる第II/III相試験(JCOG0305臨床試験). Neuro-Oncology. 15: 50-53, 2005.
渋井壮一郎:悪性グリオーマに対する化学療法ー大規模臨床試験とテーラーメイド治療ー. Jpn J Neurosurg. 15: 3-9, 2006.
渋井壮一郎:脳腫瘍に対する新しい治療. 医学のあゆみ. 222: 953-954, 2007.
成田善孝,渋井壮一郎:新しい神経疾患の動き.グリオーマ.脳神経外科ジャーナル. 25: 1242-1246, 2007.
永根基雄:悪性神経膠腫の化学療法. No Shinkei Geka 35: 433-450, 2007.
Y Narita, S Shibui: Strategy of surgery and radiation therapy for brainmetastases. Int J Clin Oncol. 14: 275-280, 2009.
S Shibui : Treatment of metastatic brain tumors. Int J Clin Oncol. 14: 273-274, 2009.
R Nishikawa: Standard therapy for glioblastoma? A review of where we are. Neurologia Medico-Chirurgica. 50: 713-719, 2010.
M Nagane: Multidisciplinary progress in neuro-oncology 2010. Lancet Neurol. 10: 18-20, 2011.

b. 主な学会発表

1. 委員会承認の治療研究

渋井壮一郎:転移性脳腫瘍の病理と治療.第24回日本脳腫瘍病理学会.2006年6月.
S Shibui, T Kayama: A clinical trial for metastatic brain tumors in Japan (JCOG 0504). 17th Joint Congress of Asia & Pacific Federations & 53rd Annual Congress of the Japan Section. Jun 2006.
渋井壮一郎、嘉山孝正:シンポジウム 悪性グリオーマの定位放射線治療.悪性グリオーマに対する多施設共同試験 -JCOG脳腫瘍グループの活動- 第15回日本定位放射線治療学会.2006年7月.
渋井壮一郎:シンポジウム19 悪性脳腫瘍に対する新規治療の展望.悪性脳腫瘍に対する化学療法の展望.第44回日本癌治療学会総会.2006年10月.
渋井壮一郎:JCOG脳腫瘍グループによる多施設共同臨床試験.第24回日本脳腫瘍学会.2006年10月.
嘉山孝正:転移性脳腫瘍に対するSRS・SRTの展望-世界標準の転移性脳腫瘍治療プロトコール.第44回日本癌治療学会総会.2006年10月.
渋井壮一郎:星細胞腫grade 3・4に対するランダム化第II/III相試験(JCOG 0305)結果.第25回日本脳腫瘍学会.2007年12月.
S Shibui: A ranodmized controlled study for malignant gliomas by JCOG-Brain Tumor Study Group. 5th Meeting of The Asian Society for Neuro-oncology. Nov 2007.
S Shibui: Clinical trials for malignant gliomas in Japan. 2007 Samsung International Brain Tumor Symposium. Sep 2007.
S Shibui: A clinical trial for metastatic brain tumors in Japan (JCOG 0504). 17th Joint Congress of Asia & Pacific Federations & 53rd Annual Congress of the Japan Section. Jun 2007.
渋井壮一郎、嘉山孝正、隈部俊宏、他: 星細胞腫grade 3・4に対するランダム化第II相試験(JCOG 0305)最終結果.第27回日本脳腫瘍学会. 2009年11月.
渋井壮一郎、他:星細胞腫grade 3/4に対するランダム化第II相試験(JCOG 0305)結果.第68回日本脳神経外科学会総会. 2009年10月.
S Shibui, JCOG-Brain Tumor Study Group: The result of a clinical trial for malig- nant gliomas by JCOG-Brain Tumors Study Group(JCOG0305). The 3rd Quadrennial Meeting of the World Federation of Neuro-oncolgy jointly with the 6th meeting of the Asian society for Neuro-Oncology. May 2009
渋井壮一郎、他: 星細胞腫grade3/4に対する第II相臨床試験(JCOG0305)における病理中央診断の意義. 第27回日本脳腫瘍病理学会. 2009年5月.
S Shibui, T Kayama, T Wakabayashi, et al.: Clinical trials for malig- nant brain tumors conducted by JCOG- Brain Tumor Study Group Clinical. The 15th Annual Scientific Meeting of the Society for Neuro-Oncology. Nov 2010.
若林俊彦、渋井壮一郎:初発膠芽腫に対するIFN-b+テモダール併用化学放射線療法のランダム化第2相試験(JCOG0911:INTEGRA phase II study). 第69回日本脳神経外科学会学術集会. 2010年10月.
若林俊彦: 悪性脳腫瘍の治療戦略におけるINTEGRA studyの果たす役割. 第29回日本脳腫瘍病理学会.2011年5月.
S Shibui, JCOG-Brain Tumor Study Group: Clinical trials conducted by JCOG-Brain Tumor Study Group. The 8th Annual Meeting of Asian Society for Neuro-Oncology. May 2011.

2. グループ代表者管理の治療研究

渋井壮一郎:悪性脳腫瘍治療におけるEBM Japan Clinical Oncology Group(JCOG)脳腫瘍研究グループの活動. 第62回日本脳神経外科学会総会. シンポジウム-8. 日本発の脳神経外科領域EBM. 2003年10月.
渋井壮一郎:放射線治療. 第63回日本癌学会総会. シンポジウム. 悪性脳腫瘍に対する新しい治療戦略. 2004年9月.
渋井壮一郎、JCOG脳腫瘍研究グループ:悪性脳腫瘍に対する多施設共同試験:JCOG脳腫瘍研究グループの活動. 第63回日本脳神経外科学会総会. シンポジウム「脳外科領域の大規模試験の現状と将来」. 2004年10月.
渋井壮一郎、淺井昭雄、嘉山孝正、他:星細胞腫Grade34に対するACNU単独療法とProcarbazine+ ACNU併用療法とのランダム化第II/III相多施設共同試験. 第22回日本脳腫瘍学会. 2004年10月.
S Shibui: Randomized controlled trial on malignant gliomas by Japan Clinical Oncology Group-Brain Tumor Study Group (JCOG-BTSG). 3rd Meeting of the Asian Society for Neuro-Oncology. Nov 2004.
渋井壮一郎:悪性脳腫瘍:標準化治療と治療抵抗性への挑戦.化学療法(標準治療とテーラーメイド化学療法の最新知見).第25回日本脳神経外科コングレス.2005年5月.
嘉山孝正:標準医療の意義と解釈ー外科の立場から.第25回日本脳神経外科コングレス.2005年5月.
S Shibui, The members of JCOG-Brain Tumor Study Group: Randomized controlled trial on malignant gliomas by JCOG-Brain Tumor Study Group (JCOG-BTSG). The 15th Annual Meeting of Korean Brain Tumor Society. Jul 2005.
渋井壮一郎:グリオーマに対する化学療法のevidence: JCOG studyを踏まえて. 第64回社団法人日本脳神経外科学会総会.2005年10月.
嘉山孝正:転移性脳腫瘍治療のスタンダード:JCOG studyを踏まえて-共同研究報告-.第64回日本脳神経外科学会総会.2005年10月.
渋井壮一郎、JCOG脳腫瘍研究グループ:悪性神経膠腫に対するJCOG脳腫瘍研究グループによる多施設共同試験. 第23回日本脳腫瘍学会.2005年10月.
S Shibui, JCOG Brain Tumor Study group:The 4th Meeting of the Asian Society for Neuro-Oncology. Nov 2005.
渋井壮一郎、宮北康二、大西晶子、他:星細胞腫grade3/4に対するACNU vs ACNU+PCZによる第II/III相試験(JCOG0305臨床試験). 第30回ニューロオンコロジイの会.2005年12月.
S Shibui, The members of JCOG-BTSG: Randomized controlled trial on malignant gliomas by JCOG-Brain Tumor Study. 2006 International Brain Tumor Research and Therapy Meeting. Apr 2006.
渋井壮一郎:シンポジウム19 悪性脳腫瘍に対する新規治療の展望.悪性脳腫瘍に対する化学療法の展望.第44回日本癌治療学会総会.2006年10月
渋井壮一郎:悪性グリオーマに対する化学療法.第25回日本脳腫瘍病理学会.2007年4月.
渋井壮一郎:悪性グリオーマ治療のスタンダード.第27回日本脳神経外科コングレス総会.2007年5月.
T Wakabayashi, A Natsume, M Fujii, et al.: Interim report of combination therapy with interferon-beta and temozolomide for malignant glioma (Integra study). XIV world congress of neurological surgery. Aug 2009.
T Wakabayashi : Present and future of management of glioma. 58th annual conference of neurological society of India. Dec 2009.
若林俊彦、渋井壮一郎、他: 悪性グリオーマの標準的治療に向けての国内の臨床試験. 第47回日本癌治療学会. 2009年10月.
S Shibui: The result of a clinical trial for malignant gliomas by JCOG-Brain Tumors Study Group. XIV World Congress of Neuro- surgery of The World Federation of Neurosurgical Societies. Sep 2009.
T Wakabayashi: Mulitomodal treatment strategy for glioma. The 4th Indian Japa- nese Friendship Neurosurgicla Meeting. Oct 2010.

3. 附随研究等

なし  

4. 総説・解説

なし